强力教授，北京大学基础医学院长聘教授、博士生导师

研究方向：代谢与衰老的机制研究与靶向干预。

Email: qiang@pku.edu.cn

简介：

强力教授长期聚焦于代谢疾病脂肪组织重构，取得一系列重要成果，获评年度代谢领域十大进展（Cell 2012）；实现脂肪组织特异靶向的原创突破，原创正电荷特异靶向内脏脂肪新策略（Nature Nanotechnology 2022）；并结合生物缓释技术实现对皮下脂肪的精确靶向减脂（Biomaterials 2023）；发明微针减肥贴获年度文章关注度第一，被 BBC、CCTV4、朝日新闻等世界媒体广泛报道和采访（ACS Nano 2017）；开发肝脏靶向纳米药物递送，改善代谢功能并避免药物肠毒性（ACS Nano 2020）。阐明代谢疾病和衰老中代谢衰退的新机制，提出新概念，开发多个新药物靶点（Cell Metabolism, 2023， 2024； JCI， 2018； Advanced Science,2023， J. Hepatology， 2020），致力实现代谢疾病的靶向精准干预。

教育经历：

(1) 2001-08 至 2007-05, 波士顿大学医学院, 生物化学，细胞与分子生物学, 博士

(2) 1997-08 至 2001-07, 北京大学, 生物技术, 学士

博士后工作经历：

(1) 2008-04 至 2011-03, 哥伦比亚大学医学系

(2) 2007-06 至 2008-03, 波士顿大学医学院

科研与学术工作经历：

(1) 2024-02 至 今, 北京大学, 基础医学院, 药理学系，教授

(2) 2023-07 至 2024-01, 哥伦比亚大学, 医学系, 终身教授（副）

(3) 2022-03 至 2024-01, 哥伦比亚大学, 病理与细胞学系, 终身教授（副）

(4) 2015-07 至 2022-02, 哥伦比亚大学, 病理与细胞学系, 助理教授

(5) 2011-04 至 2015-06, 哥伦比亚大学, 医学系, 助理研究员

近年主持的科研项目/课题：

(1) NIH/NIDDK，R01 DK131169，Adipsin in NASH

(2) NIH/NIDDK，R01 DK134471，IgG and Adipose Pathological Remodeling

(3) NIH/NIDDK，R01 DK128848，Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment

(4) NIH/NHLBI, P01, HL087123, Mechanisms of Atherogenesis in Insulin Resistance——Project

3:”PPAR Deacetylation in Cardiometabolic Disease”.

(5) NIH/NIDDK, R01, DK112943, PPAR Deacetylation in the Restoration of Metabolic Homeostasis.

(6) NIH/NIDDK, K99/R00, DK97455, Brown Remodeling of White Adipose Tissue by PPAR Deacetylation.

(7) Columbia University’s Fu Foundation School of Engineering and Applied Science Blavatnik Interdisciplinary Research Award, Molecular Scavenger Engineering to Treat Visceral Obesity.

(8) NIH/NIA, R01, DK112943-03S1, PPAR Deacetylation and Alzheimer’s disease.

(9) Russell Berrie Foundation Research Initiative on the Neurobiology of Obesity, An Immune Mechanism of Neuronal Dysregulation in Obesity.

(10) NIH/NIDDK, Pilot & Feasibility P30, DK063608, PPAR Accumulation and Metabolic Decline in Aging.

近三年代表性研究成果：

1. Yu L, Wan Q , Liu Q, Fan Y, Zhou Q, Skowronski AA, Wang S, Shao Z, Liao CY, Ding L, Kennedy B, Zha S, Que J, LeDuc CA, Sun L, Wang L^#, Qiang L^#. IgG is an aging factor to drive adipose tissue fibrosis and metabolic decline. Cell Metabolism. 2024, Feb 12:S1550-4131(24)00015-9.

2. Zahr T*, Boda VK*, Ge J*, Yu L, Wu Z, Que J^#, Li W^#, Qiang L^#. Small molecule conjugates with selective Estrogen Receptor b agonism promote anti-aging benefits in metabolism and skin recovery. Acta Pharmaceutica Sinica B. 2024, Jan 29. In press

3. Zhou Q*, Yu L*, Cook JR, Qiang L^#, Sun L^#. Deciphering the decline of metabolic elasticity in aging and obesity. Cell Metabolism. 2023 Aug 18;S1550-4131(23)00296-6.

4. Huang B*, Wan Q*, Li T*, Yu L, Du W, Carmen C, Leong KW^#, Qiang L^#. Polycationic PAMAM ameliorates obesity-associated chronic inflammation and focal adiposity. Biomaterials. 2023 Feb; 293:121850. PMID: 36450630

5. Zahr T*, Liu L*, Chan M, Zhou Q, Cai B, He Y, Aaron N, Accili D, Sun L, Qiang L. PPARγ deacetylation suppresses aging-associated atherosclerosis and hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB). 2023 Jan;43(1):30-44. PMID: 36453279

6. He Y, Taus AB, Yu L, Yao Y, Zhang R, Zahr T, Aaron N, LeSauter J, Fan L, Liu L, Tazebay R, Que J, Pajvani U, Wang L, Silver R, Qiang L. PPARγ acetylation orchestrates adipose plasticity and metabolic rhythms. Advanced Science. 2023 Jan; 10(2):e2204190.

7. Wan Q*, Huang B*, Li T, Xiao Y, He Y, Du W, Wang BZ, Fakin FG, Rosenbaum M, Goncalves MD, Chen S, Leong KW^#, Qiang L^#. Selective targeting of visceral adiposity by polycation nanomedicine. Nature Nanotechnology. 2022 Dec;17(12):1311-1321. PMID: 36456644.

Highlighted in the Nature Nanotechnology Research Briefing: https://rdcu.be/c05Wr

8. Aaron N*, Zahr T*, He Y, Yu L, Mayfield B, Pajvani UB, Qiang L. Acetylation of PPARγ in macrophages promotes visceral fat degeneration in obesity. Life Metabolism. December 2022, Vol 1 (3), 258–269.

9. Aaron N, Kraakman MJ, Zhou Q, Liu Q, Yang J, Liu L, Yu L, Wang L, He Y, Fan L, Hirakawa H, Ding L, Lo JC, Wang W, Zhao B, Guo EX, Sun L, Rosen CJ, Qiang L. Adipsin promotes bone marrow adiposity by priming mesenchymal stem cells. eLife. 2021 Jun 22;10:e69209. (Accompanied by journal press release: https://elifesciences.org/for-the-press/89b0cc02/how-a-bone-marrow-fat-hormone-controls-metabolism-and-bone-cell-development)